On June 10, 2024, Centessa Pharmaceuticals plc (the Company) announced John Crowley has been designated the Company?s principal financial officer and principal accounting officer, replacing Dr. Gregory Weinhoff as Chief Financial Officer and in those roles. On June 10, 2024 announced that the Board has appointed Dr. Gregory Weinhoff as the Company?s Chief Business Officer, on June 5, 2024, effective on the Start Date. Accordingly, Dr. Weinhoff will no longer serve as the Company?s Chief Financial Officer, principal financial officer and principal accounting officer.

Greg Weinhoff MD MBA, Chief Business Officer: Dr. Weinhoff served as Chief Financial Officer of Centessa from March 2021 to June 2024. He brings over 20 years of business development experience to the newly created position of Chief Business Officer. Prior to Centessa, Dr. Weinhoff was co-founder, director and chief financial and business officer of Arvelle Therapeutics B.V., which was acquired by Angelini Pharma in 2021.

While with Arvelle, he led the asset identification and in-licensing of cenobamate, a novel anti-seizure medicine. Prior to Arvelle, Dr. Weinhoff served as Chief Financial Officer at Axovant Sciences Inc., where he led financial functions and the execution of several private and public financings. Before Axovant, Dr. Weinhoff spent 15 years as an early-stage healthcare venture capitalist at CHL Medical Partners, where he was founding CEO of Amicus Therapeutics and his firm was the sole Series A investor.

Dr. Weinhoff holds an MD from Harvard Medical School, an MBA from Harvard Business School and an AB in economics from Harvard College. Prior to graduate school, Dr. Weinhoff was a financial analyst in Morgan Stanley & Co.?s healthcare corporate finance group. Mr. Crowley brings over 20 years of global finance and operational experience in the life sciences industry to Centessa.

He most recently served as Chief Financial Officer of Fusion Pharmaceuticals prior to its acquisition by AstraZeneca in June 2024. He also served as Executive Vice President and Chief Financial Officer of Merus Inc. Prior to Merus, Mr. Crowley served as the Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer of Charles River Laboratories Inc. Previously, Mr. Crowley held senior corporate finance positions at Ironwood Pharmaceuticals Inc., Vertex Pharmaceuticals Inc., and Sunovion Pharmaceuticals Inc., where he supported several commercial launches, financings, and business development transactions in rapidly growing companies. Mr. Crowley is a Certified Public Accountant and graduated Summa Cum Laude from Babson College with BS degrees in both Economics and Accountancy.